Nanoviricides (NNVC) risk factors
Item 1A of every Nanoviricides, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2026 10-K risk factors50 risks4 new1 dropped6 reworded
Financing is more urgent: $12.3 million is budgeted through October 2027 against insufficient cash, including $8.2 million for research and development.
Filed Sep 28, 2026 - FY2025 10-K risk factors45 risks7 reworded
Cash dropped to approximately $1.6 million, and accumulated deficit grew to approximately $149 million. Budget updates shifted focus to the MPox Phase II trial for lead candidate NV-387. Restricted shares and total outstanding share counts increased.
Filed Sep 29, 2025 - FY2024 10-K risk factors45 risks
Company faces heavy financial distress with $4.8 million in cash against an accumulated deficit of $139.4 million. Operations rely entirely on TheraCour for licensing, manufacturing, and development of nanoviricide drugs like NV-387. Regulatory approval uncertainties and the need for substantial future capital threaten long-term viability.
Filed Sep 27, 2024